Established T Cell-Inflamed Tumors Rejected After Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade

Overview

Journal Cancer Immunol Res

Specialties Allergy & Immunology
Oncology

Date 2016 Nov 9

PMID 27821498

Citations 87

Authors

Ellen Moore

Paul E Clavijo

Ruth Davis

Harrison Cash

Carter Van Waes

Young Kim

Clint Allen

Affiliations

Soon will be listed here.

Abstract

Patients with head and neck squamous cell carcinoma harbor T cell-inflamed and non-T cell-inflamed tumors. Despite this, only 20% of patients respond to checkpoint inhibitor immunotherapy. Lack of induction of innate immunity through pattern-recognition receptors, such as the stimulator of interferon (IFN) genes (STING) receptor, may represent a significant barrier to the development of effective antitumor immunity. Here, we demonstrate robust control of a T cell-inflamed (MOC1), but not non-T cell-inflamed (MOC2), model of head and neck cancer by activation of the STING pathway with the synthetic cyclic dinucleotide R,R dithio-c-di-GMP. Rejection or durable tumor control of MOC1 tumors was dependent upon a functional STING receptor and CD8 T lymphocytes. STING activation resulted in increased tumor microenvironment type 1 and type 2 IFN and greater expression of PD-1 pathway components in vivo Established MOC1 tumors were rejected and distant tumors abscopally controlled, after adaptive immune resistance had been reversed by the addition of PD-L1 mAb. These findings suggest that PD-1 pathway blockade may reverse adaptive immune resistance following cyclic dinucleotide treatment, enhancing both local and systemic antitumor immunity. Cancer Immunol Res; 4(12); 1061-71. ©2016 AACR.

Citing Articles

Nanocarrier-mediated modulation of cGAS-STING signaling pathway to disrupt tumor microenvironment.

Pindiprolu S, Singh M, Magham S, Kumar C, Dasari N, Gummadi R Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39907784 DOI: 10.1007/s00210-025-03835-3.

Elucidating the expression and role of cGAS in pan-cancer using integrated bioinformatics and experimental approaches.

Lian Z, Liu X, Li X BMC Cancer. 2025; 25(1):5.

PMID: 39748320 PMC: 11697830. DOI: 10.1186/s12885-024-13379-z.

Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma.

Vos J, Traets J, Qiao X, Seignette I, Peters D, Wouters M JCI Insight. 2024; 9(21.

PMID: 39513365 PMC: 11601749. DOI: 10.1172/jci.insight.179982.

Antagonistic roles of cGAS/STING signaling in colorectal cancer chemotherapy.

Liang B, Xing X, Storts H, Ye Z, Claybon H, Austin R Front Oncol. 2024; 14:1441935.

PMID: 39469633 PMC: 11513249. DOI: 10.3389/fonc.2024.1441935.

Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer.

Liang B, Khan M, Storts H, Zhang E, Zheng X, Xing X Mol Cancer Ther. 2024; 24(1):131-140.

PMID: 39382075 PMC: 11695182. DOI: 10.1158/1535-7163.MCT-24-0289.

References

Lemos H, Mohamed E, Huang L, Ou R, Pacholczyk G, Arbab A . STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation. Cancer Res. 2016; 76(8):2076-81. PMC: 4873329. DOI: 10.1158/0008-5472.CAN-15-1456. View

Moore E, Cash H, Caruso A, Uppaluri R, Hodge J, Van Waes C . Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers. Cancer Immunol Res. 2016; 4(7):611-20. PMC: 4930724. DOI: 10.1158/2326-6066.CIR-15-0252. View

Cash H, Shah S, Moore E, Caruso A, Uppaluri R, Van Waes C . mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer. Oncotarget. 2015; 6(34):36400-17. PMC: 4742185. DOI: 10.18632/oncotarget.5063. View

Wang Z, Celis E . STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunol Immunother. 2015; 64(8):1057-66. PMC: 4648249. DOI: 10.1007/s00262-015-1713-5. View

Ishikawa H, Ma Z, Barber G . STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature. 2009; 461(7265):788-92. PMC: 4664154. DOI: 10.1038/nature08476. View

Fu J, Kanne D, Leong M, Glickman L, McWhirter S, Lemmens E . STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med. 2015; 7(283):283ra52. PMC: 4504692. DOI: 10.1126/scitranslmed.aaa4306. View

Thomas G, Chen Z, Enamorado I, Bancroft C, Van Waes C . IL-12- and IL-2-induced tumor regression in a new murine model of oral squamous-cell carcinoma is promoted by expression of the CD80 co-stimulatory molecule and interferon-gamma. Int J Cancer. 2000; 86(3):368-74. DOI: 10.1002/(sici)1097-0215(20000501)86:3<368::aid-ijc11>3.0.co;2-1. View

Keck M, Zuo Z, Khattri A, Stricker T, Brown C, Imanguli M . Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 2014; 21(4):870-81. DOI: 10.1158/1078-0432.CCR-14-2481. View

Diamond M, Kinder M, Matsushita H, Mashayekhi M, Dunn G, Archambault J . Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011; 208(10):1989-2003. PMC: 3182061. DOI: 10.1084/jem.20101158. View

10.

Diner E, Burdette D, Wilson S, Monroe K, Kellenberger C, Hyodo M . The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep. 2013; 3(5):1355-61. PMC: 3706192. DOI: 10.1016/j.celrep.2013.05.009. View

11.

Downey C, Aghaei M, Schwendener R, Jirik F . DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization. PLoS One. 2014; 9(6):e99988. PMC: 4062468. DOI: 10.1371/journal.pone.0099988. View

12.

Woo S, Corrales L, Gajewski T . The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol. 2015; 36(4):250-6. PMC: 4393801. DOI: 10.1016/j.it.2015.02.003. View

13.

Baird J, Friedman D, Cottam B, Dubensky Jr T, Kanne D, Bambina S . Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors. Cancer Res. 2015; 76(1):50-61. PMC: 4703500. DOI: 10.1158/0008-5472.CAN-14-3619. View

14.

Curiel T, Wei S, Dong H, Alvarez X, Cheng P, Mottram P . Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003; 9(5):562-7. DOI: 10.1038/nm863. View

15.

Demaria O, de Gassart A, Coso S, Gestermann N, Di Domizio J, Flatz L . STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc Natl Acad Sci U S A. 2015; 112(50):15408-13. PMC: 4687570. DOI: 10.1073/pnas.1512832112. View

16.

Onken M, Winkler A, Kanchi K, Chalivendra V, Law J, Rickert C . A surprising cross-species conservation in the genomic landscape of mouse and human oral cancer identifies a transcriptional signature predicting metastatic disease. Clin Cancer Res. 2014; 20(11):2873-84. PMC: 4096804. DOI: 10.1158/1078-0432.CCR-14-0205. View

17.

Gajewski T, Schreiber H, Fu Y . Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013; 14(10):1014-22. PMC: 4118725. DOI: 10.1038/ni.2703. View

18.

Ishikawa H, Barber G . STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008; 455(7213):674-8. PMC: 2804933. DOI: 10.1038/nature07317. View

19.

Noman M, Desantis G, Janji B, Hasmim M, Karray S, Dessen P . PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014; 211(5):781-90. PMC: 4010891. DOI: 10.1084/jem.20131916. View

20.

Seiwert T, Burtness B, Mehra R, Weiss J, Berger R, Eder J . Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016; 17(7):956-965. DOI: 10.1016/S1470-2045(16)30066-3. View